Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination

Gastric cancer is heterogeneous in morphology, biology, genomics, and treatment response. Alterations in human epidermal growth factor receptor 2 (HER2) overexpression, microsatellite instability (MSI) status, programmed death-ligand 1 (PD-L1) levels, and fibroblast growth factor receptor 2 (FGFR2)...

Descripción completa

Detalles Bibliográficos
Autores principales: Rha, Sun Young, Chung, Hyun Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Gastric Cancer Association 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911617/
https://www.ncbi.nlm.nih.gov/pubmed/36751001
http://dx.doi.org/10.5230/jgc.2023.23.e6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911617/
https://www.ncbi.nlm.nih.gov/pubmed/36751001
http://dx.doi.org/10.5230/jgc.2023.23.e6

Ejemplares similares